Bone marrow failure syndromes. Preface.

G. Bagby,G. Meyers

DOI: https://doi.org/10.1016/j.hoc.2009.02.001

IF: 2.861

2009-04-01

Hematology/Oncology Clinics of North America

Abstract:

What problem does this paper attempt to address?

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Sarah Weber,Anastasia Parmon,Nina Kurrle,Frank Schnütgen,Hubert Serve

DOI: https://doi.org/10.3389/fimmu.2020.627662

IF: 7.3

2021-02-19

Frontiers in Immunology

Abstract:Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases leading to an insufficient formation of functional blood cells. Disease-immanent factors as insufficient erythropoiesis and treatment-related factors as recurrent treatment with red blood cell transfusions frequently lead to systemic iron overload in MDS and AML patients. In addition, alterations of function and expression of proteins associated with iron metabolism are increasingly recognized to be pathogenetic factors and potential vulnerabilities of these diseases. Iron is known to be involved in multiple intracellular and extracellular processes. It is essential for cell metabolism as well as for cell proliferation and closely linked to the formation of reactive oxygen species. Therefore, iron can influence the course of clonal myeloid disorders, the leukemic environment and the occurrence as well as the defense of infections. Imbalances of iron homeostasis may induce cell death of normal but also of malignant cells. New potential treatment strategies utilizing the importance of the iron homeostasis include iron chelation, modulation of proteins involved in iron metabolism, induction of leukemic cell death via ferroptosis and exploitation of iron proteins for the delivery of antileukemic drugs. Here, we provide an overview of some of the latest findings about the function, the prognostic impact and potential treatment strategies of iron in patients with MDS and AML.

immunology
Inherited bone marrow failure in the pediatric patient

Inderjeet Dokal,Hemanth Tummala,Tom Vulliamy

DOI: https://doi.org/10.1182/blood.2020006481

IF: 20.3

2022-08-11

Blood

Abstract:Inherited bone marrow (BM) failure syndromes are a diverse group of disorders characterized by BM failure, usually in association with ≥1 extrahematopoietic abnormalities. BM failure, which can involve ≥1 cell lineages, often presents in the pediatric age group. Furthermore, some children initially labeled as having idiopathic aplastic anemia or myelodysplasia represent cryptic cases of inherited BM failure. Significant advances in the genetics of these syndromes have been made, identifying more than 100 disease genes, giving insights into normal hematopoiesis and how it is disrupted in patients with BM failure. They have also provided important information on fundamental biological pathways, including DNA repair: Fanconi anemia (FA) genes; telomere maintenance: dyskeratosis congenita (DC) genes; and ribosome biogenesis: Shwachman-Diamond syndrome and Diamond-Blackfan anemia genes. In addition, because these disorders are usually associated with extrahematopoietic abnormalities and increased risk of cancer, they have provided insights into human development and cancer. In the clinic, genetic tests stemming from the recent advances facilitate diagnosis, especially when clinical features are insufficient to accurately classify a disorder. Hematopoietic stem cell transplantation using fludarabine-based protocols has significantly improved outcomes, particularly in patients with FA or DC. Management of some other complications, such as cancer, remains a challenge. Recent studies have suggested the possibility of new and potentially more efficacious therapies, including a renewed focus on hematopoietic gene therapy and drugs [transforming growth factor-β inhibitors for FA and PAPD5, a human poly(A) polymerase, inhibitors for DC] that target disease-specific defects.
Subkutane Konservierung einer abgetrennten Ohrmuschel

R. Staudenmaier,J. Aigner,J. Hölzl,V. Schilling,N. Rotter,A. Naumann,E. Kastenbauer

DOI: https://doi.org/10.1055/s-2000-8794

2000-04-01

Abstract:Hintergrund: Kasuistik und Ergebnisse: Schlußfolgerung: Background: Patient and Results: Conclusion:
Biology of the Bone Marrow Microenvironment and Myelodysplastic Syndromes

Erinn B. Rankin,Anupama Narla,Joseph K. Park,Shuo Lin,Kathleen M. Sakamoto

DOI: https://doi.org/10.1016/j.ymgme.2015.07.004

IF: 4.204

2015-01-01

Molecular Genetics and Metabolism

Abstract:Myelodysplastic syndromes (MDS) are characterized by cytopenias resulting from ineffective hematopoiesis with a predisposition to transform to acute myeloid leukemia (AML). Recent evidence suggests that the hematopoietic stem cell microenvironment contributes to the pathogenesis of MDS. Inflammation and hypoxia within the bone marrow are key regulators of hematopoietic stem and progenitor cells that can lead to several bone marrow failure syndromes, including MDS. In this brief review, we provide an overview of the clinical and molecular features of MDS, the bone marrow microenvironment, and specific pathways that lead to abnormal blood cell development in MDS. Characterization of key steps in the pathogenesis of MDS will lead to new approaches to treat patients with this disease. (C) 2015 Elsevier Inc. All rights reserved.
Cytogenetics in the Management of Bone Marrow Failure Syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).

Wendy Cuccuini,Marie-Agnes Collonge-Rame,Nathalie Auger,Nathalie Douet-Guilbert,Lucie Coster,Marina Lafage-Pochitaloff

DOI: https://doi.org/10.1016/j.retram.2023.103423

IF: 4.192

2023-10-19

Current Research in Translational Medicine

Abstract:Bone marrow failure syndromes are rare disorders characterized by bone marrow hypocellularity and resultant peripheral cytopenias. The most frequent form is acquired, so-called aplastic anemia or idiopathic aplastic anemia, an auto-immune disorder frequently associated with paroxysmal nocturnal hemoglobinuria, whereas inherited bone marrow failure syndromes are related to pathogenic germline variants. Among newly identified germline variants, GATA2 deficiency and SAMD9/9L syndromes have a special significance. Other germline variants impacting biological processes, such as DNA repair, telomere biology, and ribosome biogenesis, may cause major syndromes including Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome. Bone marrow failure syndromes are at risk of secondary progression towards myeloid neoplasms in the form of myelodysplastic neoplasms or acute myeloid leukemia. Acquired clonal cytogenetic abnormalities may be present before or at the onset of progression; some have prognostic value and/or represent somatic rescue mechanisms in inherited syndromes. On the other hand, the differential diagnosis between aplastic anemia and hypoplastic myelodysplastic neoplasm remains challenging. Here we discuss the value of cytogenetic abnormalities in bone marrow failure syndromes and propose recommendations for cytogenetic diagnosis and follow-up.

medicine, research & experimental
Transverse femoral arteriotomy for intraaortic balloon insertion.

D. Payne,D. H. Sewell,J. Amato,P. Faraci,H. Rheinlander,R. Cleveland

DOI: https://doi.org/10.1016/S0003-4975(10)63681-8

1978-09-01

Abstract:
Study for registry and clinical spectrum of bone marrow failure in pediatrics; single centre experience

Asmaa Abd Elrahman,Mohamed Meabed,Rehab Abd Elkareem,Yasmine Mohamed

DOI: https://doi.org/10.21608/ejmr.2022.251503

2022-07-01

Egyptian Journal of Medical Research

Abstract:Background: Bone marrow failure is a group of disorders characterized by the inability of bone marrow to produce sufficient blood cells. They can be divided into inherited disorders, acquired disorders and diseases infiltrating bone marrow. Acute leukemia is a serious cause of bone marrow failure which needs early diagnosis and management . Purpose: To study for registry, and clinical spectrum of bone marrow failure in Beni-Suef university hospital to detect the magnitude of the problem . Patients and methods: It is cross sectional study over a period of six months from January 2019 to June 2019, in which patients with bone marrow failure (monocytopenia, bicytopenia or pancytopenia) from pediatric age group (0-13 years) who were admitted in the pediatric department in Beni-Suef university hospital were included and followed up. They were subjected to a detailed history, full examination and laboratory investigation; complete blood count, reticulocyte cont, bone marrow aspirate & biopsy, virology study and accordingly other investigations were done such as flow cytometry for cd55 & cd59, glucocerebrosidase enzyme assay, chromosomal breakage analysis and imaging. Results: Out of 22000 outpatients and 1700 inpatients,55 patients had diagnosed as bone marrow failure during six months duration with percentage of o.23%. The most frequent diagnosis of bone marrow failure was acute Leukemia (30.9 %), followed by Idiopathic aplastic anemia (27.3%) then Fanconi anaemia (21.8%). Conclusion: Bone marrow failure is not rare ,acute Leukemia should be considered strongly in the diagnosis of any case of bone marrow failure.

English Else
Novel Mechanisms and Therapies of Hematopoietic Regulation

Kong Yuan,Huang Xiaojun

DOI: https://doi.org/10.12287/j.issn.2096-8965.20200104

2020-01-01

Abstract:Poor hematopoietic function is the common feature of bone marrow(BM) failure diseases. However, the pathogenesis of BM failure diseases has not been fully clarified. Under physiological conditions, the self-renewal and fate determination of hematopoietic stem cells are strictly regulated by BM microenvironment. Hematopoietic stem cell transplantation is not only an effective way to treat leukemia, but also an ideal model to study hematopoietic regulation. Moreover, poor hematopoietic reconstitution after transplantation is a good disease modelfor the study of BM failure diseases. Taken together, the successful implementation of translational studies based onnovel mechanisms may provide novel therapeutic strategies for patients with BM failure diseases in the future.
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

Zahra Hudda,Kasiani C. Myers

DOI: https://doi.org/10.1182/hematology.2023000471

2023-12-09

Hematology, the ASH Education Program

Abstract:Inherited bone marrow failure syndromes (IBMFS) encompass a group of rare genetic disorders characterized by bone marrow failure, non-hematologic multisystemic comorbidities, disease defining congenital anomalies, and a susceptibility to myelodysplastic syndrome, acute myeloid leukemia, and in some instances solid tumors. The most common IBMFS include Fanconi anemia, Shwachman-Diamond syndrome, Diamond-Blackfan anemia, and telomere biology disorders/ dyskeratosis congenita. Allogeneic hematopoietic stem cell transplant (HCT) is a well-established curative treatment to correct the hematological manifestations but does not halt or reverse the nonhematological complications and may hasten them. With advances in HCT and in our ability to care for patients with IBMFS, an increasing number of survivors are making it imperative to not only diagnose but also treat late effects from the pre-, peri-, and post-HCT course and complications relating to the natural history of the syndrome. As the field of HCT evolves to allow for the incorporation of alternate graft sources, for expansion of donor options to include unrelated and mismatched donors, and for use of reduced-intensity conditioning or reduced toxicity myeloablative regimens, we have yet to determine if these advances modify the disease-specific course. While long-term outcomes of these patients are often included under one umbrella, this article seeks to address disease-specific post-HCT outcomes within IBMFS.
Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure

Jonathan Paolino,Nancy Berliner,Barbara Degar

DOI: https://doi.org/10.3389/fonc.2022.1016318

IF: 4.7

2022-10-28

Frontiers in Oncology

Abstract:Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of multiorgan system dysfunction that is caused by hypercytokinemia and persistent activation of cytotoxic T lymphocytes and macrophages. A nearly ubiquitous finding and a diagnostic criterion of HLH is the presence of cytopenias in ≥ 2 cell lines. The mechanism of cytopenias in HLH is multifactorial but appears to be predominantly driven by suppression of hematopoiesis by pro-inflammatory cytokines and, to some extent, by consumptive hemophagocytosis. Recognition of cytopenias as a manifestation of HLH is an important consideration for patients with bone marrow failure of unclear etiology.

oncology
Myelodysplastic Neoplasms Evolving from Inherited Bone Marrow Failure Syndromes / Germline Predisposition Syndromes: Back under the Microscope

M. Tarek Elghetany,Mrinal M. Patnaik,Joseph D. Khoury

DOI: https://doi.org/10.1016/j.leukres.2024.107441

IF: 3.715

2024-01-25

Leukemia Research

Abstract:Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or more cell lines. Yet, the diagnosis of MDS is usually associated with a worse outcome in several IBMFS/GPS. Criteria for the diagnosis of MDS in IBMFS/GPS have not been standardized with some authors suggesting a mixture of morphologic, cytogenetic, and genetic criteria. This review highlights these challenges and suggests a more standardized approach to nomenclature and diagnostic criteria.

oncology,hematology
Low-dose non-steroidal anti-inflammatory drugs: a promising approach for the treatment of symptomatic bone marrow failure in Ghosal hematodiaphyseal dysplasia

Jonathan Bordat,Felipe Suarez,Valérie Cormier-Daire,Regis Peffault De Latour,Jean Soulier,Veronique Meignin,Mathilde Doyard,Lise Larcher,Stephane Vanderbecken,Flore Sicre De Fontbrune

DOI: https://doi.org/10.3324/haematol.2023.284098

2024-03-19

Haematologica

Abstract:Not available. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

hematology
Somatic mosaicism in inherited bone marrow failure syndromes

Fernanda Gutierrez-Rodrigues,Sushree S Sahoo,Marcin W Wlodarski,Neal S Young

DOI: https://doi.org/10.1016/j.beha.2021.101279

Abstract:Inherited bone marrow failure syndromes (IBMFS) are a heterogenous group of diseases caused by pathogenic germline variants in key pathways associated with haematopoiesis and genomic stability. Germline variants in IBMFS-related genes are known to reduce the fitness of hematopoietic stem and progenitor cells (HSPC), which has been hypothesized to drive clonal selection in these diseases. In many IBMFS, somatic mosaicism predominantly impacts cells by two distinct mechanisms, with contrasting effects. An acquired variation can improve cell fitness towards baseline levels, providing rescue of a deleterious phenotype. Alternatively, somatic mosaicism may result in a fitness advantage that results in malignant transformation. This review will describe these phenomena in IBMFS and delineate their relevance for diagnosis and clinical management. In addition, we will discuss which samples and methods can be used for detection of mosaicism according to clinical phenotype, type of mosaicism, and sample availability.
Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes

Hirotoshi Sakaguchi,Nao Yoshida

DOI: https://doi.org/10.1007/s12185-022-03362-4

Abstract:Inherited bone marrow failure syndromes (IBMFSs) are a group of rare genetic disorders characterized by bone marrow failure with unique phenotypes and predisposition to cancer. Classical IBMFSs primarily include Fanconi anemia with impaired DNA damage repair, dyskeratosis congenita with telomere maintenance dysfunction, and Diamond-Blackfan anemia with aberrant ribosomal protein biosynthesis. Recently, comprehensive genetic analyses have been implemented for the definitive diagnosis of classic IBMFSs, and advances in molecular genetics have led to the identification of novel disorders such as AMeD and MIRAGE syndromes. Allogeneic hematopoietic cell transplantation (HCT), a promising option to overcome impaired hematopoiesis in patients with IBMFSs, does not correct nonhematological defects and may enhance the risk of secondary malignancies. Disease-specific management is necessary because IBMFSs differ in underlying defects and are associated with varying degrees of risk for clonal evolution and early or late complications after HCT. In addition, long-term follow-up is essential to detect complications related to the IBMFS or HCT. This review provides a summary of current clinical practices along with the latest data on HCT in IBMFSs.
Comprehensive review of solid tumor bone marrow metastasis

Lanxin Zhang,Fengxi Chen,Lingzhi Xu,Ning Li,Qiping Zhuo,Yijin Guo,Xueqing Wang,Meijie Wen,Zuowei Zhao,Man Li

DOI: https://doi.org/10.1016/j.critrevonc.2023.104248

IF: 6.625

2023-12-26

Critical Reviews in Oncology/Hematology

Abstract:Bone marrow metastasis (BMM) of solid tumors refers to a group of diseases that originate from non-hematopoietic malignant tumor cells invading the bone marrow (BM) through complex metastatic patterns. If BMM identification is delayed, the disease will rapidly develop into disseminated carcinogenesis of the BM, which manifests as a series of hematological disorders and microangiopathic hemolytic anemia, leading to serious life-threatening conditions. Although the study of solid tumor BMM is receiving increasing attention, study remains limited, and most descriptions are derived from case reports. Currently, clinicians have insufficient understanding of BMM, and BMM occurrence is often not recognized early or treated effectively, resulting in high mortality rates. In this article, we review the epidemiology, molecular mechanisms, clinical diagnosis, treatment, and prognosis of solid tumor BMM.

oncology,hematology
Enhanced cellular immune response in women with PTSD related to childhood abuse.

M. Altemus,M. Cloitre,F. Dhabhar

DOI: https://doi.org/10.1176/APPI.AJP.160.9.1705

IF: 17.7

2003-09-01

American Journal of Psychiatry

Abstract:OBJECTIVE Disturbed regulation of both the hypothalamic-pituitary-adrenal (HPA) axis and the sympathoadrenomedullary system in posttraumatic stress disorder (PTSD) suggests that immune function, which is modulated by these systems, also may be dysregulated in individuals with PTSD. METHOD Delayed-type hypersensitivity skin test responses were measured in 16 women with PTSD due to childhood sexual or physical abuse and 15 women who did not have a history of abuse, other trauma, or psychiatric disorders. HPA axis activity was assessed by examination of circadian salivary cortisol levels and a single time point measurement of plasma cortisol. RESULTS Delayed-type hypersensitivity was enhanced in women with PTSD. Cortisol measures did not differ between PTSD and healthy comparison subjects. CONCLUSIONS These results suggest that cell-mediated inflammatory reactions are greater in individuals with PTSD.
The molecular pathogenesis of myelodysplastic syndromes

Matthew S Davids,David P Steensma

DOI: https://doi.org/10.4161/cbt.10.4.12612

2010-08-15

Abstract:The myelodysplastic syndromes (MDS) are frequently associated with clonally restricted cytogenetic abnormalities, but until recently, the molecular pathobiology underlying this diverse group of neoplastic bone marrow disorders has been largely obscure. During the last 10 years, many investigative groups have applied the formidable power of new molecular biology techniques to hunt for recurrent genetic alterations in MDS primary cells. Several genetic abnormalities, including mutations in RUNX1 (AML1), TET2, ASXL1 and TP53, have been discovered in a substantial fraction of MDS cases; genes rearranged or mutated less commonly in MDS include IER3, ATRX, RAS and FLT3. Furthermore, haploinsufficiency and expression changes in RPS14, miR-145 and miR-146a, CDC25c, PP2A and SPARC in the absence of point mutations have also been implicated in MDS pathobiology. A major challenge will be to determine which of these mutations are causative "drivers" either in the development or progression of MDS, which might be therapeutically important because they predict response to treatment, and which are merely "passengers" along for the ride that alter phenotype but have no effect on the natural history of the disease. While the altered cellular biology of MDS is also increasingly well-understood, many mysteries remain. Abnormalities in iron regulation, microenvironment interactions, regulation of apoptosis and oxidative damage/DNA repair may all play an important pathobiological role. By gaining a deeper understanding of the mechanisms of these complex and heterogeneous diseases, we will hopefully improve our ability to treat our patients with MDS beyond the therapies with limited effectiveness that are available at present.
Malignant progression of pre-leukemic disorders

Trent Hall,Sandeep Gurbuxani,John D Crispino,John D. Crispino

DOI: https://doi.org/10.1182/blood.2023020817

IF: 20.3

2024-03-19

Blood

Abstract:The spectrum of myeloid disorders ranges from aplastic bone marrow failure characterized by an empty bone marrow completely lacking in hematopoiesis to acute myeloid leukemia where the marrow space is replaced by undifferentiated leukemic blasts. Recent advances in the capacity to sequence bulk tumor population as well as at a single cell level has provided significant insight into the stepwise process of transformation to acute myeloid leukemia. Using models of progression in the context of germline predisposition (trisomy 21, GATA2 deficiency, SAMD9/9L syndrome), premalignant states (clonal hematopoiesis and clonal cytopenia of unknown significance) and myelodysplastic syndrome, we review the mechanisms of progression focusing on the hierarchy of clonal mutation and potential roles of transcription factor alterations, splicing factor mutations and the bone marrow environment in progression to acute myeloid leukemia. Despite major advances in our understanding, preventing progression of these disorders or treating them at the acute leukemia phase remains a major area of unmet medical need.

hematology
Sauerstoffgabe bei akutem Myokardinfarkt

M. Christ

DOI: https://doi.org/10.1007/s10049-010-1314-y

2010-08-26

Notfall + Rettungsmedizin

Abstract:
Bone marrow necrosis: Facts, controversies, and perspective

Chengxin Luan,Hongguo Zhao,Yufei Ding

DOI: https://doi.org/10.1111/ijlh.14335

2024-06-27

International Journal of Laboratory Hematology

Abstract:Bone marrow necrosis (BMN) is a clinically and pathologically poorly‐defined and readily‐overlooked entity. The current facts and guidelines pertaining to this entity are scarce, and there exist controversies. Upon reviewing the literature, we present the facts, analyze these controversies, and discourse on future prospects.

hematology

Bone marrow failure syndromes. Preface.

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Inherited bone marrow failure in the pediatric patient

Subkutane Konservierung einer abgetrennten Ohrmuschel

Biology of the Bone Marrow Microenvironment and Myelodysplastic Syndromes

Cytogenetics in the Management of Bone Marrow Failure Syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).

Transverse femoral arteriotomy for intraaortic balloon insertion.

Study for registry and clinical spectrum of bone marrow failure in pediatrics; single centre experience

Novel Mechanisms and Therapies of Hematopoietic Regulation

Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

Hemophagocytic lymphohistiocytosis as an etiology of bone marrow failure

Myelodysplastic Neoplasms Evolving from Inherited Bone Marrow Failure Syndromes / Germline Predisposition Syndromes: Back under the Microscope

Low-dose non-steroidal anti-inflammatory drugs: a promising approach for the treatment of symptomatic bone marrow failure in Ghosal hematodiaphyseal dysplasia

Somatic mosaicism in inherited bone marrow failure syndromes

Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes

Comprehensive review of solid tumor bone marrow metastasis

Enhanced cellular immune response in women with PTSD related to childhood abuse.

The molecular pathogenesis of myelodysplastic syndromes

Malignant progression of pre-leukemic disorders

Sauerstoffgabe bei akutem Myokardinfarkt

Bone marrow necrosis: Facts, controversies, and perspective